Korean J Intern Med.
2004 Jun;19(2):109-113.
A Less Intensive Combination of Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer Patients who Have Aged 60 Years or More and Has a Poor Performance Status
- Affiliations
-
- 1Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
- 2Department of Radiation Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
- 3Department of Pathology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
- 4Department of Thoracic Surgery, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
- 5Department of Radiology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
- 6Department of Internal Medicine, Chungbuk National University, Medical School, Cheongju Korea. kimlee@chungbuk.ac.kr
Abstract
- BACKGROUND
The aim of this study was to evaluate the response, survival, and toxicities of a less intensive combination of paclitaxel and carboplatin, which is used in advanced non-small cell lung cancer (NSCLC) patients older than 60 years of age including those with a poor performance status. METHODS: Thirty patients received 135 mg/m2 of paclitaxel on day 1, and carboplatin was administered to the patients on day 1 every 4 weeks over an area under the concentration-time curve of 6. RESULTS: The response rate was 40%, the median overall survival was 9.1 months (95% CI, 4.2 to 14 months), and the 1 year survival rate was 31%. The median progression-free survival was 7.7 months (95% CI, 3.1 to 12.2 months). In addition, the toxicities were generally mild and reversible. CONCLUSION: This study demonstrates that a less intensive combination of paclitaxel/carboplatin is active and well tolerated in advanced NSCLC patients who are older than 60 years including those with a poor PS 3~4.
Keyword
MeSH Terms
-
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
Carboplatin/administration & dosage/adverse effects
Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Lung Neoplasms/*drug therapy/pathology
Male
Middle Aged
Neoplasm Staging
Paclitaxel/administration & dosage/adverse effects
Sickness Impact Profile
Survival Analysis
Treatment Outcome
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Case of Recurrent Cervical Cancer Responded to Paclitaxel and Carboplatin Combination
- Efficacy of Combination Chemotherapy with Paclitaxel and Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer
- A Phase II Study with Gemcitabine and Carboplatin in Patients with Advanced Non-small Cell Lung Cancer
- A case of neoadjuvant chemotherapy with taxol / carboplatin in advanced epithelial ovarian cancer
- Clinical Response of Docetaxel Plus Cisplatin and Paclitaxel Plus Carboplatin Chemotherpy in Non-Small Cell Lung Cancer
